1 / 6
Verified Lab Results
Finished in the USA
Research Use OnlyGrowth Factor & Tissue Signaling Research · Popular Peptides
$91.20$45.60Save 50%
Tesamorelin is a synthetic peptide made in the laboratory — a stabilized version of the natural signal that prompts the pituitary gland to release growth hormone.
Research groups order it to study GHRH-receptor pharmacology, growth hormone pulsatility and the GH/IGF-1 axis, and fat-cell lipolysis signalling in preclinical models. Supplied strictly for laboratory research use only.
Quantity
$45.60
Tesamorelin 10mg · 10mg
$45.60$91.20
Bundle & save
For Research Use Only. Not for human consumption or therapeutic treatment.
Compound Class and Structure
Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone releasing hormone (GHRH), supplied as a lyophilized white powder in sealed vials for laboratory research use only. The sequence corresponds to full-length GHRH(1–44), with a trans-3-hexenoyl group attached at the N-terminal tyrosine. This acyl modification sterically shields the N-terminus from dipeptidyl peptidase-4 (DPP-4) cleavage — the principal enzymatic route that fragments native GHRH in plasma and serum-containing culture media — so the intact molecule persists across longer assay windows than the unmodified parent sequence.
Receptor Pharmacology and Signalling
The molecular target is the GHRH receptor (GHRHR), a class B1 secretin-family G protein-coupled receptor expressed densely on anterior pituitary somatotrophs. Agonist occupancy drives Gs coupling, adenylyl cyclase activation and cyclic AMP accumulation, with downstream protein kinase A activity, CREB phosphorylation and GH1 transcriptional readouts, alongside voltage-gated calcium entry that supports secretory granule release. Released growth hormone then engages hepatic and peripheral growth hormone receptors, activating JAK2/STAT5 signalling and IGF-1 and IGFBP-3 expression. Because somatostatinergic tone and IGF-1 feedback shape the same circuit, the analogue is widely used as a probe of feedback architecture rather than of a single receptor in isolation.
Research Areas, Models and Endpoints
In vitro work uses primary pituitary cell cultures and GHRHR-transfected reporter lines, with endpoints including radioligand or fluorescent binding affinity, cAMP accumulation, luciferase reporter output, secreted growth hormone measured by immunoassay, and transcript abundance by qPCR. In rodent and other preclinical models, serial sampling protocols characterise pulse amplitude, interpulse interval and area-under-curve profiles of circulating growth hormone, together with IGF-1, IGFBP-3 and somatostatin-related markers. Adipose research applies isolated adipocyte and explant systems, measuring glycerol and non-esterified fatty acid release into supernatant, hormone-sensitive lipase and ATGL phosphorylation states, perilipin turnover, and depot-specific lipolytic gene expression indices. Analytical and enzymology groups use DPP-4 incubation assays with chromatographic and mass-spectrometric fragment profiling to compare degradation kinetics against unmodified GHRH.
Storage and Laboratory Documentation
As laboratory documentation for the lyophilized material: store sealed vials cold, dark and dry. Long-term inventory is generally held at approximately -20 °C, with short-term holding at 2–8 °C acceptable for working stock. Keep vials in their original light-resistant packaging or a closed secondary container, since ultraviolet and visible light exposure can promote degradation of peptide powders. Maintain desiccated conditions and avoid repeated warming and re-cooling of sealed material, which encourages condensation and moisture uptake. Good practice is to log the lot number, receipt date and storage location on receipt, and to archive the lot-specific certificate of analysis alongside internal records so that analytical identity and study data remain traceable.
Regulatory Status
This material is sold for research use only. It is not a drug, is not approved for any therapeutic indication, and is not for human or veterinary use, diagnostic use, or any household application. Purchase is limited to qualified researchers and institutional buyers working in appropriately equipped laboratory settings under applicable local rules and institutional oversight.
Tesamorelin is a stabilized 44-amino-acid analogue of growth hormone releasing hormone (GHRH), offered as a lyophilized laboratory reference material for research use only. Its defining structural feature is a trans-3-hexenoyl modification at the N-terminal tyrosine, which resists DPP-4 cleavage and keeps the full-length sequence intact through longer experimental windows than native GHRH.
Functionally, it behaves as an agonist at the GHRH receptor, a class B1 G protein-coupled receptor concentrated on anterior pituitary somatotrophs. Investigators use it as a pharmacological tool to trigger and then characterise endogenous growth hormone release, tracking cyclic AMP signalling in cell systems and pulse architecture in preclinical models.
Because the molecule works upstream — through a receptor rather than by supplying growth hormone directly — it is frequently selected for studies of intact endocrine feedback, including somatostatin tone and IGF-1-mediated regulation of the axis.
Real Peptides supplies Tesamorelin as a research-use-only laboratory material backed by documentation rather than marketing claims. Every lot is submitted to an independent analytical laboratory, and the resulting certificate of analysis is published and tied to the specific lot code printed on the vial, so identity and purity data can be matched to the exact material received.
Material arrives as lyophilized powder in factory-sealed, stoppered multi-use vials with intact seals for tamper evidence. Page formats are 3mg, 5mg, 10mg, 10ml and 40mg, letting laboratories align inventory with study scale and storage capacity.
Orders are picked, packed and dispatched from United States stock, with packaging selected to shield the powder from light and heat in transit. Lot records are retained internally, and support staff can supply the matching certificate of analysis for audit trails, method validation files or institutional procurement review.
Tesamorelin sits in the GHRH-analogue class, and that mechanism class is what differentiates it scientifically. It engages the GHRH receptor on somatotrophs, so growth hormone appears in episodic, feedback-shaped bursts. Compounds in the ghrelin-receptor secretagogue class act through a separate receptor and signalling pathway, while direct recombinant growth hormone preparations bypass the pituitary entirely and flatten the pulsatile signal researchers often want to preserve.
Against unmodified GHRH and its shortened fragment analogues, the trans-3-hexenoyl group is the practical distinction: reduced susceptibility to DPP-4 cleavage yields more consistent intact-peptide exposure in serum-containing media and in preclinical sampling designs.
Compared with metabolic research compounds acting on incretin or nutrient-sensing receptor classes, Tesamorelin addresses adipocyte lipolysis signalling indirectly through the GH/IGF-1 axis. That upstream position makes it a cleaner probe for endocrine feedback questions and for separating receptor-level from hormone-level effects.
Growth Factor & Tissue Signaling Research compounds
Ships within 24 hours
Free standard shipping on orders $250+
Lab report included
